Recent Updates
Recently added Catalysts
APYX Positive Sentiment

Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference

Key Takeaway: Apyx Medical Corporation announced its participation in the Canaccord Genuity 46th Annual Growth Conference scheduled for August 11, 2026. CEO Charlie Goodwin and CFO Matt Hill will engage in a fireside chat and hold one-on-one meetings with investors. The event will be accessible via live webcast, promoting transparency and investor engagement.
Price reaction · baseline $3.89 (2026-07-27 close) · hit pre-market · clean, no other APYX news in the window
day 0 close · peak
-0.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prominent industry conference enhances visibility.
  • Management engagement with investors through fireside chat and meetings.
  • Strong product offerings supported by clinical documentation.

Full Press Release Details

CLEARWATER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System ™ (AYON), today announced that management will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA.
Charlie Goodwin, the Company’s President and Chief Executive Officer, and Matt Hill, the Company’s Chief Financial Officer, will participate in a fireside chat on Tuesday, August 11, 2026, at 2:30pm ET and will hold one-on-one meetings with investors throughout the day. The fireside chat will be accessible via live webcast here, and a replay will be available on the Events section of Apyx Medical’s Investor Relations website at https://apyxmedical.com/investor_relations/.

About Apyx Medical Corporation:

Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® and the AYON Body Contouring System ™ in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, electrosurgical capabilities and Renuvion for tissue contraction, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.

Investor Relations Contact: Jeremy Feffer Managing Director LifeSci Advisors OP: 212-915-2568 jfeffer@lifesciadvisors.com

Frequently Asked Questions

When is Apyx Medical participating in the conference?

Apyx Medical will participate in the conference on August 11, 2026.

Who will represent Apyx Medical at the conference?

CEO Charlie Goodwin and CFO Matt Hill will represent Apyx Medical.

How can investors access the fireside chat?

The fireside chat will be accessible via live webcast on the company's website.

What products does Apyx Medical offer?

Apyx Medical offers Renuvion and AYON Body Contouring System in surgical aesthetics.

Last updated: Jul 28, 2026